Effect of RA233 on metastasis in dogs with osteosarcomas.
The influence of RA233, an inhibitor of platelet function, on the occurrence of metastasis in 18 dogs with osteosarcomas was evaluated. At least 24 hours before surgical removal of the primary tumor, dogs were given RA233 orally (20 mg/kg of body weight divided into 3 equal doses). Original sites of the osteosarcoma included humerus, 6 dogs; radius, 5 dogs; tibia, 3 dogs; femur, 2 dogs; maxilla, 1 dog; and mandible, 1 dog. Survival time for 13 dogs euthanatized for progression of neoplastic disease ranged from 3 months to 10 months, with a mean survival time of 5.5 months. Medication was discontinued in 1 dog because of possible adverse reaction. One dog died of disease unrelated to the tumor, and one dog was euthanatized after the surgery. Two dogs were tumor free 9 and 17 months after surgery. Seemingly, the metastasis potential was not diminished in dogs given 20 mg of RA233/kg/day.
D000818:Animals; D001859:Bone Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000517:prevention & control; D004285:Dogs; D005260:Female; D008297:Male; D009012:Mopidamol / Q000627:therapeutic use*; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D012516:Osteosarcoma / Q000188:drug therapy / Q000556:secondary / Q000662:veterinary*; D011743:Pyrimidines / Q000627:therapeutic use*
D011743:Pyrimidines; D009012:Mopidamol